'via Blog this'
DHS Wants Defense Distributed’s Plastic Gun
RF and Nick did their best to keep Austin weird last night by schmoozing dining with Defense Distributed’s main brain, Cody Wilson. Among the interesting tidbits they pried out of him thanks to the liberal application of great food and French wine is that Big Sis wants one of his guns. That’s right, DHS wants to give a Liberator the full going over, no doubt to see how well the TSA’s blue-gloved gropers who man airport security operations can ID a printed plastic handgun. Here’s their email exchange . . .
On May 7, 2013 12:58 PM, “Levine, Bob” wrote:
Cody
We are contractors for a government agency and hold an FFL license for them. We have been instructed find out what the cost to purchase this gun would be along with time frame for delivery.
We are contractors for a government agency and hold an FFL license for them. We have been instructed find out what the cost to purchase this gun would be along with time frame for delivery.
Hopefully you can respond asap as we have a presentation to give
<><><><><><><><><><><><><><>
Bob Levine
SRA International
Senior Director
SRA International
Senior Director
<><><><><><><><><><><><><><>
From: Cody Wilson
Sent: Tuesday, May 07, 2013 2:03 PM
To: Levine, Bob
Subject: Re: liberator- TSA requirement
Sent: Tuesday, May 07, 2013 2:03 PM
To: Levine, Bob
Subject: Re: liberator- TSA requirement
Bob,
The gun is not for sale. It is an experimental prototype. I’ll lend or make you one of you like, but better to put them in contact with me.
The gun is not for sale. It is an experimental prototype. I’ll lend or make you one of you like, but better to put them in contact with me.
From: “Levine, Bob”
Date: May 7, 2013 1:24 PM
Subject: RE: liberator- TSA requirement
To: “Cody Wilson”
Cc:
Date: May 7, 2013 1:24 PM
Subject: RE: liberator- TSA requirement
To: “Cody Wilson”
Cc:
Cody
Thank you for the quick response.
Thank you for the quick response.
Have forwarded your response to the PM- will let you know if there is anything we will need
<><><><><><><><><><><><><><>
Bob Levine
SRA International
Senior Director
SRA International
Senior Director
<><><><><><><><><><><><><><>
The first theme is introduced in the membrane-bound receptors, including epidermal growth factor receptor (EGFR) family of receptors, from Spain, from the University Hospital Vall Desi Buren (Vall d'Hebron University Hospital) in Dr.Josep Tabernero be described. Since 75% to 90% of CRC patients can be observed in the expression of EGFR and EGFR are indicators of poor prognosis, researchers in the EGFR family of receptors for a lot of work, so that cetuximab and Panitumumab is approved for the treatment of CRC KRAS wild-type, both of which are the scope of the extracellular region of EGFR monoclonal antibodies. Such new trial including GA201, SYM004 studies (SYM004 can degrade and removal of cell surface receptors), as well as cetuximab and immunomodulatory drugs to that degree by the combination. It also discusses other membrane-bound receptors, including insulin-like growth (ILG) factor receptor, platelet-derived growth factor receptor (PDGFR), HCF c-Met receptor ligand and tumor necrosis factor-related apoptosis-inducing ligand body (TRAIL) receptors.
ReplyDeleteSimilarly, in the CRC research is promising scope intracellular signal transduction pathway components of the drug, this topic from the United States University of Colorado Dr.Wells Messersmith introduced. He discussed the ongoing development of promising new drugs, these drugs act on the MAPK, PI3K, SRC, Notch and hebgehog signal transduction pathway. Many drugs currently being carried out for various types of cancer in stage Ⅰ and Ⅱ early clinical trials. Expect these promising new approach in the near future for the clinician to bring more treatment options.
Finally, from the University of Texas Cancer Center Dr.Scott Kopetz MDAnderson introduced for the treatment of CRC angiogenesis inhibitors. To anti-vascular endothelial growth factor monoclonal antibody bevacizumab high success rate of the treatment begins, Dr.Kopetz recalled from the first generation and second generation angiogenesis inhibitors such as vatalanib and cediranib treatment failure of lessons learned, noting grasp early in the drug development process VEGF inhibitors pharmacokinetic importance "Unfortunately, there is no evidence that in addition to bevacizumab other than anti-angiogenic drugs can provide meaningful clinical benefit," Dr.Kopetz said he proposed a possible exception.
Medchemexpress Can provide the above product,its website:www.medchemexpress.com
BAY 61-3606 dihydrochloride
E-3810
BAY 61-3606
Cabozantinib S-malate
Pazopanib
Axitinib
OSI-930
Cediranib
MP470
Motesanib Diphosphate